Skip to main content
Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Publisher: Bentham Science Publishers

More about this publication?
Volume 12, Number 22, 2006

Articles

Favourites:
ADD

Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
pp. 2723-2747(25)
Authors: Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H.

Favourites:
ADD

Integrins in Drug Targeting-RGD Templates in Toxins
pp. 2749-2769(21)
Authors: Lu, X.; Lu, D.; Scully, M. F.; Kakkar, V. V.

Favourites:
ADD
Favourites:
ADD

Targeting T-Cell Adhesion Molecules for Drug Design
pp. 2797-2812(16)
Authors: Jois, Seetharama D.S.; Jining, Liu; Nagarajarao, Latha M.

Favourites:
ADD

Structure and Function of the Intercellular Junctions: Barrier of Paracellular Drug Delivery
pp. 2813-2824(12)
Authors: Zheng, Kai; Trivedi, Maulik; Siahaan, Teruna J.

Favourites:
ADD

Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
pp. 2825-2831(7)
Authors: Mrowietz, Ulrich; Boehncke, Wolf-Henning

Favourites:
ADD

Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
pp. 2833-2848(16)
Authors: Bewick, Mary A.; Lafrenie, Robert M.

Favourites:
ADD

Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
pp. 2849-2861(13)
Authors: Syrigos, Konstantinos N.; Karayiannakis, Anastasios J.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content